|
Oliver-Caldes A, Espanol-Rego M, Zabaleta A, Gonzalez-Calle V, Navarro-Velazquez S, Inoges S, de Cerio AL, Cabanas V, Lopez-Munoz N, Rodriguez-Otero P, Reguera JL, Moreno DF, Martinez-Cibrian N, Lopez-Corral L, Perez-Amill L, Martin-Antonio B, Rosinol L, Cid J, Tovar N, Saez-Penataro J, Lopez-Parra M, Olesti E, Guillen E, Varea S, Rodriguez-Lobato LG, Battram AM, Gonzalez MS, Sanchez-Salinas A, Gonzalez-Navarro A, Ortiz-Maldonado V, Delgado J, Prosper F, Juan M, Martinez-Lopez J, Moraleda JM, Mateos MV, Urbano-Ispizua A, Paiva B, Pascal M, Fernandez de Larrea C. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. Clin Cancer Res. 2024 May 15;30(10):2085-2096. doi: 10.1158/1078-0432.CCR-23-3759. PubMed PMID: 38466644.
AÑO: 2024; IF: 10.0
|
38466644